AZD1775 + AZD1775 Matching Placebo + pemetrexed + carboplatin
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer
Conditions
Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer
Trial Timeline
Mar 1, 2014 → Jun 1, 2015
NCT ID
NCT02087241About AZD1775 + AZD1775 Matching Placebo + pemetrexed + carboplatin
AZD1775 + AZD1775 Matching Placebo + pemetrexed + carboplatin is a phase 2 stage product being developed by AstraZeneca for Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT02087241. Target conditions include Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02087241 | Phase 2 | Terminated |
Competing Products
8 competing products in Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR-A1811 + Pyrotinib in combination with Capecitabine. + SHR-A1811 | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| AZD1775 + AZD1775 Placebo + Antimitotic Agent + pegfiligrastim | AstraZeneca | Phase 2 | 52 |
| UFOX + Cetuximab + FOLFOX4 + Cetuximab | Merck | Phase 2 | 52 |
| Idelalisib + Nab-paclitaxel + mFOLFOX6 | Gilead Sciences | Phase 1 | 32 |
| Bosutinib | Pfizer | Approved | 84 |
| CRS-207 + CRS-207 + nivolumab + GVAX + CY | Bristol Myers Squibb | Phase 2 | 51 |
| Lenalidomide + Dexamethasone + Elotuzumab | Bristol Myers Squibb | Phase 3 | 76 |
| Oxaliplatin | Sanofi | Phase 2 | 51 |